Overlap of functional dyspepsia and irritable bowel syndrome by revised Rome IV criteria: meta-analysis

Abstract

Introduction. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) overlap is an adverse clinical situation, as patients with this syndrome have more severe clinical manifestations resulting in significant reductions in quality of life. For now, there are no meta-analytical papers that would summarize the frequency of FD – IBS overlap using the revised Rome IV criteria. Objective. To organize data on the prevalence of FD – IBS overlap using the revised Rome IV criteria.Materials and methods. A search for studies was conducted in MEDLINE / PubMed, EMBASE, Cochrane electronic databases. The search depth was 6 years (from January 2016 to February 2021). The final analysis included original publications from peerreviewed periodicals that used the revised Rome IV criteria as a method for diagnosing FD and IBS in the adult population with detailed descriptive statistics allowing to include resulting data in the meta-analysis.Results and discussion. The final analysis included 6 studies involving 1,180 patients with PD and 600 patients with IBS. The generalized prevalence of IBS in patients with PD was 41.511% (95% CI: 22.203–62.288). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 94.28%). The generalized prevalence of PD in patients with IBS was 38.791% (95% CI: 9.438–73.710). The analysis was undertaken by using a random-effects model, as there was significant heterogeneity among results (p < 0.0001; I2 = 99.25%).Сonclusion. The complete meta-analysis showed that the frequency of FD - IBS overlap using the revised Rome IV criteria is quite high and accounts for about 40%. At the same time, further large studies of more homogeneous structure are needed to verify these results and study the potential pathogenetic relationship between PD and IBS.

"An Attempt to Present First Potential Medication for Overlap Dyspepsia with Nonspecific/Unspecified Irritable Bowel Syndrome by Patients’ Self-Assessment"

“…The practical situation becomes even more complicated when overlapping symptoms. It should be noted that publications note significant differences in the reported incidence of intersection syndromes in DGBI and virtually no evaluation of the drug treatment efficacy and safety for such conditions [22,23]. It has also been shown that the natural history in people with IBS overlapping FD is more severe than in those with isolated IBS [24].…”

Efficacy and Safety Clarification of Alverin with Simethicone Combination in Dyspepsia with Intestinal Symptoms Overlap Syndrome by Available in Real Clinical Practice Indicators and Patients’ Self-Assessment

“…Следует обратить внимание на то, что в публикациях отмечаются значительные различия приводимых данных о частоте синдромов перекреста при DGBI и практически отсутствуют работы по оценке эффективности и безопасности медикаментозного лечения таких состояний [22,23]. Также показано, что естественное течение болезни у людей с СРК, перекрывающимся ФД, более тяжелое, чем у людей с изолированным СРК [24].…”